Hospital-Based Management of Opioid Use Disorder in the Fentanyl Era—The Role and Limits of Expert Consensus - Scorecard - MDSpire

Hospital-Based Management of Opioid Use Disorder in the Fentanyl Era—The Role and Limits of Expert Consensus

  • By

  • Itai Danovitch

  • May 7, 2026

Share

Clinical Scorecard: Managing Opioid Use Disorder in Hospitals During the Fentanyl Crisis—Expert Consensus Insights and Limitations

At a Glance

CategoryDetail
Condition
Key MechanismsFentanyl's high potency, unpredictable withdrawal trajectories, and the impact of emerging additives and adulterants complicate treatment.
Target Population
Care Setting

Key Highlights

  • Hospitalized patients often present with complex medical issues, including trauma, pain management, and psychiatric comorbidities, affecting OUD treatment.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Implement toxicology surveillance and public health advisories to monitor emerging contaminants, including local intelligence on prevalence.

      Risks

        Patient & Prescribing Data

        Hospitalized individuals with opioid use disorder, particularly those affected by fentanyl.

        Engagement with addiction consultation services improves post-discharge MOUD access.

        Clinical Best Practices

        • Adopt standardized protocols while ensuring individualized patient assessments and modifications based on clinical context.

        Related Resources & Content

        Original Source(s)

        Hospital-Based Management of Opioid Use Disorder in the Fentanyl Era—The Role and Limits of Expert Consensus

        • by Itai Danovitch

        • May 7, 2026

        Related Content

        GLP-1 RAs Associated With Small ION Risk Increase

        In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.

        10 CMS and FDA Actions Affecting Care in 2026

        From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.

        A meta-analysis of the efficacy of limus-coated balloons vs. paclitaxel-coated balloons for coronary artery disease